Immune Checkpoint Inhibitors Market is expected to reach US$ 156.6 billion by 2031 | Major Companies - Bristol-Myers Squibb Company., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, AstraZeneca.

Market Size and Growth:

The Global Immune Checkpoint Inhibitors Market size reached US$ 40.1 billion in 2023 and is expected to reach US$ 156.6 billion by 2031, growing at a CAGR of 16.5% during the forecast period 2024-2031.

The Immune Checkpoint Inhibitors Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/immune-checkpoint-inhibitors-market?sz

The Immune Checkpoint Inhibitors (ICI) Market encompasses the global trade and development of drugs that block immune checkpoint proteins, enhancing the body's immune response against cancer. These therapies target proteins like PD-1, PD-L1, and CTLA-4, improving survival rates in various cancers. The market includes drug development, clinical trials, approvals, manufacturing, and distribution worldwide.

Recent Key Developments of United States:

✅ November: FDA approved lurbinectin plus atezolizumab (PD-L1 inhibitor) as maintenance therapy for extensive-stage small cell lung cancer after first-line chemo-immunotherapy, improving overall and progression-free survival in the IMforte trial.

✅ November: FDA approved durvalumab (PD-L1 inhibitor) with FLOT chemotherapy as neoadjuvant/adjuvant therapy for resectable gastric/gastroesophageal junction adenocarcinoma, showing significant event-free survival benefits in the MATTERHORN trial.

✅ October: FDA approved cemiplimab (PD-1 inhibitor) for adjuvant treatment of adults with high-risk cutaneous squamous cell carcinoma following surgery and radiation, based on improved disease-free survival in the C-POST trial.

Recent Key Developments of Europe:

✅ December: European market sees sustained growth in checkpoint inhibitors via streamlined EMA processes and national reimbursements, with increased clinical trials and partnerships boosting access for aging populations.

✅ November: US FDA subcutaneous pembrolizumab (Keytruda Qlex, PD-1 inhibitor) approval highlights formulation advances relevant to Europe, where PD-1/PD-L1 inhibitors hold over 60% market share amid rising combination therapy adoption in Germany and UK.

✅ October: EMA's CHMP issued a positive opinion for cemiplimab (Libtayo, PD-1 inhibitor) as adjuvant therapy for high-risk cutaneous squamous cell carcinoma post-surgery and radiation, aligning with recent US FDA approval and pending final EC decision.

List of the Key Players in the Immune Checkpoint Inhibitors Market:

Bristol-Myers Squibb Company.
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
AstraZeneca
Regeneron Pharmaceuticals, Inc.
Eli Lilly and Company
BeiGene LTD.
GSK plc
Coherus BioSciences, Inc.
lncyte.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/immune-checkpoint-inhibitors-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Immune Checkpoint Inhibitors Market:

By Type: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, LAG-3 Inhibitors, Others.

By Application: Breast Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Hodgkin Lymphoma, Liver Cancer, Lung Cancer, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=immune-checkpoint-inhibitors-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Immune Checkpoint Inhibitors market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Immune Checkpoint Inhibitors Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Immune Checkpoint Inhibitors market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Immune Checkpoint Inhibitors Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Immune Checkpoint Inhibitors Market in 2025?
◆ What is the projected growth rate of the Immune Checkpoint Inhibitors Market through 2033?
◆ Who are the key players in the Immune Checkpoint Inhibitors Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.